Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edgewise Therapeutics Inc. Common Stock vs Cassava Sciences Inc — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.3 (market cap $4.02B), while Cassava Sciences Inc trades at $0.71 (market cap $35.34M). The key difference: Edgewise Therapeutics Inc. Common Stock is far larger — about 113.8× Cassava Sciences Inc's market cap, and Edgewise Therapeutics Inc. Common Stock is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Cassava Sciences Inc for 38 Days on average.
| EWTX | FLNA | |
|---|---|---|
Market Cap | $4.02B | $35.34M |
Volume | 1,446,128 | 251,946 |
Sector | Health | Health |
52-Week High | $48.35 | $4.64 |
52-Week Low | $14.89 | $0.68 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $3.56B | -$47.34M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $0.7434, down 3.39% today, with a bearish technical signal despite recent positive FDA news lifting a clinical hold on its epilepsy drug. The company shows improving quarterly EPS beats but remains unprofitable with negative cash flows. Analyst consensus is strongly bullish with 8 buy ratings versus 4 holds.
The outlook hinges on clinical progress—FDA clearance enables Phase 2a trials in 2027, a key catalyst. Risks include sustained cash burn and fiduciary concerns highlighted in recent news. Investors should weigh the high analyst optimism against fundamental weaknesses and regulatory execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Edgewise Therapeutics Inc. Common Stock
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
